Shots:
- Evotec to receive $179M/ product as upfront, research funding and milestones along with the royalties on sales of the therapies while Novo Nordisk will lead the clinical development and commercialization of the therapies
- The companies will share responsibilities during drug discovery and pre-clinical development and will jointly identify and develop novel targets based on medical and molecular data sets of thousands of CKD patients
- The collaboration allows Novo Nordisk to expand its portfolio beyond diabetes targeting the unmet medical needs of patients
Click here to read full press release/ article | Ref: Novo Nordisk | Image: GMP News
